The glycosylation in SARS-CoV-2 and its receptor ACE2
Y Gong, S Qin, L Dai, Z Tian - Signal Transduction and Targeted …, 2021 - nature.com
Abstract Coronavirus disease 2019 (COVID-19), a highly infectious disease caused by
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has infected more than …
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has infected more than …
Altered glycosylation in cancer: A promising target for biomarkers and therapeutics
Glycosylation is a well-regulated cell and microenvironment specific post-translational
modification. Several glycosyltransferases and glycosidases orchestrate the addition of …
modification. Several glycosyltransferases and glycosidases orchestrate the addition of …
Targeting tumor glycans for cancer therapy: successes, limitations, and perspectives
N Berois, A Pittini, E Osinaga - Cancers, 2022 - mdpi.com
Simple Summary Aberrant glycosylation is a common feature of many cancers, and it plays
crucial roles in tumor development and biology. Cancer progression can be regulated by …
crucial roles in tumor development and biology. Cancer progression can be regulated by …
Targeting the siglec–sialic acid immune axis in cancer: current and future approaches
H Läubli, SC Nalle, D Maslyar - Cancer immunology research, 2022 - AACR
The sialic acid–binding immunoglobulin-like lectin (Siglec)–sialic acid immune axis is an
evolutionarily conserved immunoregulatory pathway that provides a mechanism for …
evolutionarily conserved immunoregulatory pathway that provides a mechanism for …
Upregulation of GALNT7 in prostate cancer modifies O-glycosylation and promotes tumour growth
Prostate cancer is the most common cancer in men and it is estimated that over 350,000
men worldwide die of prostate cancer every year. There remains an unmet clinical need to …
men worldwide die of prostate cancer every year. There remains an unmet clinical need to …
Mapping of truncated O-glycans in cancers of epithelial and non-epithelial origin
Background Novel immunotherapies targeting cancer-associated truncated O-glycans Tn
(GalNAcα-Ser/Thr) and STn (Neu5Acα2–6GalNacα-Ser/Thr) are promising strategies for …
(GalNAcα-Ser/Thr) and STn (Neu5Acα2–6GalNacα-Ser/Thr) are promising strategies for …
Aberrant glycosylation as immune therapeutic targets for solid tumors
Y Matsumoto, T Ju - Cancers, 2023 - mdpi.com
Simple Summary Glycosylation is one of the most pivotal post-translational modifications on
all types of biomolecules for the formation of glycoproteins, glycolipids, and glycoRNAs in a …
all types of biomolecules for the formation of glycoproteins, glycolipids, and glycoRNAs in a …
A sweet warning: mucin-type O-glycans in cancer
Y Zhang, L Sun, C Lei, W Li, J Han, J Zhang, Y Zhang - Cells, 2022 - mdpi.com
Glycosylation is a common post-translational modification process of proteins. Mucin-type O-
glycosylation is an O-glycosylation that starts from protein serine/threonine residues …
glycosylation is an O-glycosylation that starts from protein serine/threonine residues …
The Tn antigen promotes lung tumor growth by fostering immunosuppression and angiogenesis via interaction with Macrophage Galactose-type lectin 2 (MGL2)
V da Costa, SJ van Vliet, P Carasi, S Frigerio… - Cancer letters, 2021 - Elsevier
Tn is a tumor-associated carbohydrate antigen that constitutes both a diagnostic tool and an
immunotherapeutic target. It originates from interruption of the mucin O-glycosylation …
immunotherapeutic target. It originates from interruption of the mucin O-glycosylation …
Targeting Solid Cancers with a Cancer-Specific Monoclonal Antibody to Surface Expressed Aberrantly O-glycosylated Proteins
The lack of antibodies with sufficient cancer selectivity is currently limiting the treatment of
solid tumors by immunotherapies. Most current immunotherapeutic targets are tumor …
solid tumors by immunotherapies. Most current immunotherapeutic targets are tumor …